REGENXBIO (RGNX) Revenue & Revenue Breakdown
REGENXBIO Revenue Highlights
Latest Revenue (Y)
$90.24M
Latest Revenue (Q)
$24.20M
Main Segment (Y)
License and Service
REGENXBIO Revenue by Period
REGENXBIO Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $90.24M | -19.94% |
2022-12-31 | $112.72M | -76.03% |
2021-12-31 | $470.35M | 204.30% |
2020-12-31 | $154.57M | 338.70% |
2019-12-31 | $35.23M | -83.88% |
2018-12-31 | $218.50M | 2002.42% |
2017-12-31 | $10.39M | 126.48% |
2016-12-31 | $4.59M | -39.52% |
2015-12-31 | $7.59M | 23.99% |
2014-12-31 | $6.12M | 0.54% |
2013-12-31 | $6.09M | - |
REGENXBIO Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $24.20M | 8.53% |
2024-06-30 | $22.30M | 42.72% |
2024-03-31 | $15.62M | -29.67% |
2023-12-31 | $22.21M | -23.18% |
2023-09-30 | $28.91M | 44.74% |
2023-06-30 | $19.98M | 4.38% |
2023-03-31 | $19.14M | -38.94% |
2022-12-31 | $31.34M | 18.23% |
2022-09-30 | $26.51M | -18.80% |
2022-06-30 | $32.65M | 46.95% |
2022-03-31 | $22.22M | -94.43% |
2021-12-31 | $398.65M | 1195.47% |
2021-09-30 | $30.77M | 39.66% |
2021-06-30 | $22.04M | 16.69% |
2021-03-31 | $18.88M | -11.94% |
2020-12-31 | $21.45M | -78.32% |
2020-09-30 | $98.91M | 497.08% |
2020-06-30 | $16.57M | -6.11% |
2020-03-31 | $17.64M | 49.93% |
2019-12-31 | $11.77M | -19.95% |
2019-09-30 | $14.70M | 86.52% |
2019-06-30 | $7.88M | 791.52% |
2019-03-31 | $884.00K | -97.83% |
2018-12-31 | $40.78M | 668.51% |
2018-09-30 | $5.31M | -86.75% |
2018-06-30 | $40.03M | -69.76% |
2018-03-31 | $132.39M | 6389.75% |
2017-12-31 | $2.04M | 52.69% |
2017-09-30 | $1.34M | -79.64% |
2017-06-30 | $6.56M | 1342.20% |
2017-03-31 | $455.00K | -73.17% |
2016-12-31 | $1.70M | 1256.80% |
2016-09-30 | $125.00K | -94.74% |
2016-06-30 | $2.38M | 504.33% |
2016-03-31 | $393.00K | -91.16% |
2015-12-31 | $4.45M | 290.18% |
2015-09-30 | $1.14M | -16.36% |
2015-06-30 | $1.36M | 111.65% |
2015-03-31 | $644.00K | -43.90% |
2014-12-31 | $1.15M | 137.68% |
2014-09-30 | $483.00K | - |
REGENXBIO Revenue Breakdown
REGENXBIO Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
License and Service | $90.24M | $112.72M | - | - | - |
License And Service | - | - | $470.35M | $154.57M | - |
License | - | - | - | - | $3.50M |
Zolgensma Royalties | - | - | - | - | $20.83M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
License and Service | $24.20M | $22.30M | $15.62M | $70.27M | $19.98M | $31.34M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
License And Service | - | - | - | - | - | $19.14M | $26.51M | $32.65M | $22.22M | $398.65M | $30.77M | $22.04M | $18.88M | - | - | - | - | - | - | - |
Zolgensma Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $20.91M | $18.80M | $11.95M | $9.98M | $10.72M | - |
License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.50M | $3.50M | - | - |
Achievement Of Sales Based Milestone For Zolgensma | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.00M | - | - | - | - |
Latest
REGENXBIO Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
IMCR | Immunocore | $249.43M | $75.40M |
MIRM | Mirum Pharmaceuticals | $186.37M | $77.88M |
RGNX | REGENXBIO | $90.24M | $24.20M |
PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
QURE | uniQure | $15.84M | $2.29M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
KZR | Kezar Life Sciences | $7.00M | - |
CRNX | Crinetics Pharmaceuticals | $4.01M | - |
PLRX | Pliant Therapeutics | $1.58M | - |
LIAN | LianBio | - | - |
ANTX | AN2 Therapeutics | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
REPL | Replimune Group | - | - |
RCKT | Rocket Pharmaceuticals | - | - |
PASG | Passage Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
FDMT | 4D Molecular Therapeutics | - | - |